Weaker expectations for the oil & gas business

07/11/19 -"This led to an impairment (92% for goodwill) on the former Rhodia and Chemlogics activities (Novecare – Advance Formulations), which damaged the Q3 figures and came fully out of the blue. In ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

07/11/19

Download

You may also be interested by these reports :

12/09/25

Siltronic AG

There was a change of analyst for the coverage of Slitronic AG. We have now revised our figures for the company and incorporated the latest Q2 ...

02/09/25

Idea Kicker

We last commented on Yara (ADD ; Norway) around 13 months ago, taking a positive stance on the global fertilizer manufacturer, largely backed by the ...

29/08/25

Yara International

For 2025, the upgrade to EPS stems from the factors below: 1. The largest contributor to the increase – update to the impact of FX on financial ...

28/08/25

BRAIN Biotech AG

Subdued 9M results – Slight guidance trim, funding visibility remains key

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue

Solvay